J 2023

Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy

KLAIL, Tomáš; Petra ŠEDOVÁ; Jan VINKLÁREK; Ingrid KOVACOVA; Michal BAR et. al.

Základní údaje

Originální název

Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy

Autoři

KLAIL, Tomáš; Petra ŠEDOVÁ; Jan VINKLÁREK; Ingrid KOVACOVA; Michal BAR; Filip CIHLAR; David CERNIK; Lubomir KOCI; René JURA; Roman HERZIG; Jakub HUSTÝ; Martin KOCHER; Martin KOVAR; Miroslava NEVSIMALOVA; Jan RAUPACH; Miloslav ROCEK; Daniel SANAK; Petr SEVCIK; David SKOLOUDIK; Martin SRAMEK; Jiří VANÍČEK; Peter VASKO; Daniel VACLAVIK; Ales TOMEK a Robert MIKULÍK

Vydání

Journal of vascular and interventional radiology, New York, ELSEVIER, 2023, 1051-0443

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.600

Kód RIV

RIV/00216224:14110/23:00131949

Organizační jednotka

Lékařská fakulta

UT WoS

001068364800001

EID Scopus

2-s2.0-85162254024

Klíčová slova česky

THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES

Klíčová slova anglicky

THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 5. 4. 2024 08:50, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: To investigate the safety and efficacy of baseline antiplatelet treatment in patients with acute ischemic stroke (AIS) undergoing mechanical thrombectomy (MT). Materials and Methods: Baseline use of antiplatelet medication before MT for (AIS) may provide benefit on reperfusion and clinical outcome but could also carry an increased risk of intracranial hemorrhage (ICH). All consecutive patients with AIS and treated with MT with and without intravenous thrombolysis (IVT) between January 2012 and December 2019 in all centers performing MT nationwide were reviewed. Data were prospectively collected in national registries (eg, SITS-TBY and RES-Q). Primary outcome was functional independence (modified Rankin Scale 0-2) at 3 months; secondary outcome was ICH. Results: Of the 4,351 patients who underwent MT, 1,750 (40%) and 666 (15%) were excluded owing to missing data from the functional independence and ICH outcome cohorts, respectively. In the functional independence cohort (n = 2,601), 771 (30%) patients received antiplatelets before MT. Favorable outcome did not differ in any antiplatelet, aspirin, and clopidogrel groups when compared with that in the no-antiplatelet group: odds ratio (OR), 1.00 (95% CI, 0.84-1.20); OR, 1.05 (95% CI, 0.86-1.27); and OR, 0.88 (95% CI, 0.55-1.41), respectively. In the ICH cohort (n = 3,685), 1095 (30%) patients received antiplatelets before MT. The rates of ICH did not increase in any treatment options (any antiplatelet, aspirin, clopidogrel, and dual antiplatelet groups) when compared with those in the no-antiplatelet group: OR, 1.03 (95% CI, 0.87-1.21); OR, 0.99 (95% CI, 0.83-1.18); OR, 1.10 (95% CI, 0.82-1.47); and OR, 1.43 (95% CI, 0.87-2.33), respectively. Conclusions: Antiplatelet monotherapy before MT did not improve functional independence or increase the risk of ICH.

Návaznosti

90249, velká výzkumná infrastruktura
Název: CZECRIN IV